ChronicleBio

ChronicleBio is a data-driven biotechnology company founded in 2025 and headquartered in Menlo Park, CA. The firm is developing an advanced platform using artificial intelligence to analyze complex biological data and accelerate drug discovery for neuroimmune conditions. It specifically targets historically overlooked and under-researched chronic illnesses such as Postural Orthostatic Tachycardia Syndrome (POTS), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and Long COVID.

The company was co-founded by CEO Rohit Gupta, a leader in biobanking and precision medicine with previous roles at Stanford and UCSF; Fidji Simo, former CEO of Instacart and a senior executive at OpenAI and Meta; and Executive Chairman Rishi Reddy of Tarsadia Investments. The founding vision is deeply personal, as Simo and Reddy have been diagnosed with chronic conditions the company is researching, and Gupta's family is also affected. This personal connection fuels their mission to address the significant gaps in understanding and treating these complex diseases.

ChronicleBio's business model centers on creating a comprehensive, ethically sourced data ecosystem. This platform integrates multi-omic data—including genomics, epigenetics, and proteomics—with clinical information, real-world evidence, and patient-reported outcomes. By building this rich, longitudinal dataset, the company aims to identify distinct biological signatures of disease and stratify patients based on the underlying mechanisms of their conditions. This approach enables biopharmaceutical companies, researchers, and clinics to access integrated datasets for biomarker discovery and to design more precise and effective clinical trials. The company's revenue streams are expected to derive from providing this foundational infrastructure and its insights to partners in the pharmaceutical and research sectors. In July 2026, ChronicleBio secured $10.3 million in an early-stage venture capital funding round.

The core of ChronicleBio's offering is its "Internet of Biology" platform, which addresses two fundamental challenges: the lack of deep, disease-specific human data and the limited understanding of human biology. The platform is designed to source multimodal data, create an interconnected data ecosystem, and train large biological AI models to uncover novel therapeutic insights. The company has established partnerships with clinics and research collaborators in the U.S. and India and engages directly with patients to contribute data and biosamples. A significant collaboration launched in 2025 involves organizations like Solve M.E. and the Brain Inflammation Collaborative, uniting decades of data to accelerate breakthroughs. In June 2026, the company appointed John Mumm, PhD, a seasoned immunology innovator and serial founder, as its Chief Scientific Officer to bolster its drug development expertise.

Keywords: AI drug discovery, chronic disease, neuroimmune disorders, multi-omic data, precision medicine, data platform, biobanking, patient stratification, biomarker discovery, translational science, ME/CFS, Long COVID, POTS, biotechnology, computational biology, Rohit Gupta, Fidji Simo, Rishi Reddy, complex chronic conditions, clinical trials, therapeutic development, human data, biological models